Twist Bioscience announced that Nicholas Naclerio, Illumina's senior VP of corporate development and general manager of enterprise informatics, will join its board. Before his current position at Illumina, he was its SVP of corporate and venture development. He previously was the co-founder and chairman of Quanterix.
Cypher Genomics has appointed Catherine 'Kitty' Mackey to its scientific advisory board. Mackey is currently the CEO of Cyprus Therapeutics. Previously, she was senior vice president of worldwide research and development for Pfizer and director of Pfizer La Jolla laboratories. She also worked as a member of the executive team at Dekalb Genetics before the company was bought by Monsanto.
Condie Carmack has joined GenomOncology as vice president of translational medicine, where he is responsible for the firm's oncology products and services and its newest venture in constitutional medicine. Carmack joins GenomOncology from Vela Diagnostics, where he was director of oncology programs. Before that, he helped form the Cancer Genetics Laboratory at Baylor College of Medicine with Marilyn Li. He was general manager of the lab for two years and previously held positions at Agilent Technologies, Molecular Dynamics, and GenPharm.
Mya Thomae, Harjit Kullar
Transgenomic has elected Mya Thomae to its board of directors. She is currently vice president of regulatory affairs at Illumina. Before that, she served as CEO of Myraqa, a diagnostics regulatory consulting firm, which was acquired by Illumina in 2014.
Transgenomic has also appointed Harjit Kullar vice president of marketing for biomarker discovery and genetic assays and platforms. He previously was content marketing leader for cross-functional global digital and web-based initiatives at Bio-Rad. Before that, he was director of product marketing, genomics, at Thermo Fisher Scientific.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.